Lupin Limited Secures CDP Double 'A' for Climate and Water

Lupin Limited, a major pharmaceutical company on a global scale, reported that the Climate Disclosure Project granted it an 'A' leadership rating for both Climate Change and Water Security.

As a result of this recognition, Lupin Limited is positioned with a number of other global companies that are raising the bar for Corporate Sustainability, Corporate Accountability, and Transparent Corporate Environmental Reporting.

The double ‘A’ CDP rating highlights Lupin Limited’s strong focus on lowering carbon emissions, managing climate risks, and driving responsible water use across its operations. The achievement marks a sharp improvement over recent years. Lupin was rated ‘A-’ in both climate and water in 2024, while in 2023 it received a ‘B’ for climate and a ‘C’ for water, showing steady and measurable progress year after year.

Also Read: How Digital Maturity is Powering Pharma's GMP Evolution

Commenting on the milestone, Ramesh Swaminathan, executive director, global CFO and head – API Plus SBU, Lupin, said, “As a global pharma leader, we have significantly advanced our efforts to reduce environmental impact through innovation, collaboration, and transparency. We are proud to have earned CDP’s Double ‘A’ rating. CDP’s strict framework has helped shape and accelerate our climate initiatives, fostering ongoing progress. We are committed to establishing new sustainability standards and generating lasting value for our communities and the planet.”

In addition to their recognition from CDP, Lupin Limited received an S&P Global ESG score of 91 in 2025, which represents a world-leading performance in this area. Because it was able to achieve a score above 90, Lupin joins the ranks of a small number of companies that have been recognized as leaders in Environmental, Social, and Governance (ESG) Practices, further establishing itself as a leader in the area of Sustainable Pharmaceutical Manufacturing.